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Dear Editor,
Since the initial report of KIT mutations in subtypes of
melanoma, several reports of KIT-targeted therapies
have been published (Carvajal et al., 2009; Hodi et al.,
2008; Lutzky et al., 2008). Activating KIT mutations have
been documented in a variety of neoplastic diseases
including, in addition to melanoma, mastocystosis, acute
myeloid leukemia, seminoma and gastrointestinal stro-
mal tumors (Went et al., 2004). Herein, we report a
case of a KIT double mutation in anorectal melanoma
not previously described in melanoma, but with a
response to imatinib mesylate that might have been
expected given the knowledge from other cancers.
The patient is an 87-year-old woman who developed
constipation and a palpable rectal mass in the summer
of 2009. Biopsy of the mass demonstrated an ulcerated
melanoma invading the submucosa and muscle to a
depth of approximately 11 mm with angiolymphatic
invasion. Computerized tomography (CT) scans of the
chest, abdomen and pelvis revealed metastatic disease
in the pelvis, inguinal region and lungs. Substantial
growth of the disease was documented on serial CT
scans 3 months apart with the largest lung nodule
increasing 44% (14 to 25 mm). The patient declined
treatment with systemic chemotherapy and was not a
candidate for the available clinical trials but she did
express an interest in some form of therapy. Her mela-
noma was assessed for KIT mutational status. A double
mutation was identified, comprising the exon 11 muta-
tion V559A and the exon 17 mutation N822I. The
patient subsequently initiated treatment with imatinib
400 mg daily in November 2009. Surveillance CT scans
in February 2010 revealed that most metastatic lesions
were stable to minimally decreased, including a right
inguinal lymph node (16 to 14 mm), a right upper lobe
lung nodule (20 to 18 mm), a right lower lobe lung nod-
ule (25 to 23 mm) and a right ischioanal lesion (19 to
15 mm). There was complete disappearance of multiple
subcentimetre lung nodules; however, there was also
some growth of other lung nodules, the largest of
which increased from 25 to 28 mm. The findings were
consistent with a mixed response, although in accor-
dance with RECIST criteria, the patient’s response
would best be classified as stable disease (7%
decrease in sum of diameters of target lesions). No
repeat biopsy was attempted. The dose of imatinib was
titrated from 400 to 800 mg with the aim of overcoming
any possible resistance to therapy and improving the
patient’s response. Unfortunately, the patient developed
significant fatigue, dyspnea on exertion and lower
extremity edema. Treatment was held, and after recov-
ery from these acute symptoms, attempts were made
to reinitiate imatinib at the lower dose of 400 mg. The
patient was not able to tolerate resumption of therapy,
and she experienced further clinical decline and progres-
sion of disease; ultimately, she succumbed to her meta-
static melanoma in August, 2010.
Efforts to define the genetic landscape of melanomas
have led to the recognition that alterations in the KIT
gene constitute the predominant mutation in melano-
mas arising from chronic sun-damaged skin and acral
and mucosal anatomical locations (Curtin et al., 2005,
2006). KIT mutations in melanoma are now only begin-
ning to be catalogued. The experience with KIT muta-
tions in GISTs, however, is much more extensive, and
this experience provides a conceptual framework for
understanding the pathobiology of and therapeutic
approaches to treating neoplastic diseases driven by KIT
mutations (Corless and Heinrich, 2008). KIT mutations
underlie approximately 85% of GISTs; and the vast
majority (70%) occurs within exon 11 corresponding
to the autoinhibitory juxtamembrane domain. KIT exon 9
lies within the extracellular ligand-binding region, and
mutations within this exon account for 10 to 15% of
KIT mutations in GIST. KIT mutations within the kinase
domain (either exon 13 or exon 17) occur with much
less frequency (<5%). To date, molecular analyses have
identified approximately two dozen unique KIT muta-
tions in melanoma (Woodman and Davies, 2010). Simi-
lar to GIST, the majority of KIT mutations in melanoma
occur within the juxtamembrane autoinhibitory region
encoded by exon 11. Unique to melanoma, though, the
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L576P mutation represents the most frequent site of
genetic alteration, accounting for one-third of all KIT
mutations in melanoma. Mutations within the kinase
domains, exons 13, 17 or 18 represent approximately
one-third of mutations. And, to date, in melanoma, one
case of a KIT mutation in the extracellular domain, exon
9, has been reported (Carvajal et al., 2009).
The recognition of KIT-mutated cancers has afforded
the opportunity for targeted therapeutic interventions,
specifically the implementation of tyrosine kinase inhibi-
tors. Overall, between 75 and 90% of patients with
GISTs who are treated with the tyrosine kinase inhibitor,
imatinib, experience a clinical benefit (Heinrich et al.,
2006). An individual patient’s sensitivity to imatinib,
though, in large measure depends upon the specific KIT
mutation that they harbor. Exon 11 KIT mutations dem-
onstrate the highest response rate to imatinib. Exon 9
mutations exhibit some resistance to imatinib; however,
this resistance can be overcome by increasing the dose
of imatinib (Debiec-Rychter et al., 2006; Gramza et al.,
2009). KIT mutations within the exon 17 kinase domain
show variable resistance. In GIST, as well as with semi-
noma, acute myeloid leukemia and mastocystosis, pri-
mary resistance to imatinib has been observed with the
KIT exon 17 D816V, D816G and D820E ⁄Y KIT mutations
(Debiec-Rychter et al., 2005; Heinrich et al., 2003). In
contrast, partial imatinib responses have been reported
in patients with KIT exon 17 N822K, N822H or Y823D
mutations (Debiec-Rychter et al., 2006; Heinrich et al.,
2003, 2006; Kemmer et al., 2004). The experience with
treating KIT-mutated melanomas with imatinib and tyro-
sine kinase inhibitors remains in the early phases. Thus
far, though, reports of responsiveness in melanoma
generally accord with the imatinib responses observed
in other KIT-mutated neoplasms (Satzger et al., 2010).
Adding to the complexity of effective therapeutics,
double KIT mutations have been documented in both
GIST and melanoma. With GIST, both primary and sec-
ondary (post-imatinib therapy) double KIT mutations
have been reported. Primary double KIT mutations,
though, are rare in GIST. Heinrich et al. (2006) in a ser-
ies of greater than 1000 patients with GIST reported a
single primary double KIT mutation, K642E (exon 13)
with N822K (exon 17). Four primary double mutations in
melanoma have thus far been identified: N566D (exon
11) ⁄K642E (exon 13) (Curtin et al., 2006), N463S
(exon 9) ⁄N655S (exon 13) (Carvajal and Al, 2009),
K642E (exon 13) ⁄N822I (exon 17) (Torres-Cabala et al.,
2009) and V559A (exon 11) ⁄N822I (exon 17) (this
report). Secondary KIT mutations, after imatinib use, are
much more frequent, with secondary KIT mutations in
exons 13, 14 or 17 accruing to precedent exon 9 or 11
mutations (Antonescu et al., 2005; Chen et al., 2004;
Corless and Heinrich, 2008; Debiec-Rychter et al., 2005;
Grimpen et al., 2005; Heinrich et al., 2006; Tamborini
et al., 2004; Wardelmann et al., 2005, 2006). To our
knowledge, no secondary KIT mutations have been
reported in patients with melanoma after treatment with
imatinib. But this is most probably attributable to the
only recent therapeutic utilization of imatinib to treat
melanoma.
With GIST, KIT double mutations respond variably to
imatinib therapy. Frequently, KIT mutations that individu-
ally respond to imatinib may demonstrate resistance
when they occur in tandem (Heinrich et al., 2006). In
accordance with the observed responsiveness of single
KIT mutations either at exon 11 or at exon 17 N822 posi-
tion in GIST, the current report suggests that in mela-
noma, the exon 11 V559A + exon17 N822I double
mutation remains to some degree imatinib sensitive, but
the benefit is likely marginal. Resistance to imatinib has
led to the assessment of alternative tyrosine kinase inhib-
itors for KIT-mutated cancers. For example, the tyrosine
kinase inhibitors PKC412, sunitinib and nilotinib have all
been observed to demonstrate selective activity against a
variety of specific non-exon 11 imatinib-resistant KIT
mutations (Chan et al., 2009; Growney et al., 2005), and
utilization of these alternative tyrosine kinase inhibitors
might appropriately be considered as first-line choices for
patients when non-exon 11 mutations are identified.
The treatment options for metastatic melanoma
remain limited. For patients with metastatic disease of
the mucosal, anorectal or acral lentiginous type, KIT
mutational analysis may reveal additional therapeutic
opportunities. Continued progress will depend on the
careful discovery and documentation of single and multi-
ple KIT mutations in melanoma and their unique pat-
terns of responsiveness to tyrosine kinase inhibition.
The utility of such a strategy has previously been dem-
onstrated in the treatment of other malignancies driven
by tyrosine kinase inhibitor-sensitive mutations (Redaelli
et al., 2009). The currently existing data on KIT muta-
tions in melanoma as well as in other cancers, such as
GIST, provide a relative predictability of response to
tyrosine kinase inhibition that we believe should be
used to guide future clinical trial designs and to person-
alize treatment regimens off protocol. The current
report, demonstrating at best stabilization of exon 11
V559A + exon17 N822I double-mutated melanoma with
imatinib therapy, contributes to this end.
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